Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-03-01
2011-03-01
Russel, Jeffrey E (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200
Reexamination Certificate
active
07897561
ABSTRACT:
The invention includes a method for the treatment or prophylaxis of atherosclerosis, and/or for the treatment or prophylaxis of reperfusion injury in a subject in need of treatment by administering to the subject a therapeutically effective amount of a complement inhibitor. The complement inhibitor may be a molecule which can inhibit activation of at least one complement component, inhibit activity of at least one activated complement component, act as an antagonist against at least one complement receptor, or combinations thereof. The complement inhibitor can be a vaccinia virus complement control protein (VCP).
REFERENCES:
patent: 5157110 (1992-10-01), Kotwal et al.
patent: 5187268 (1993-02-01), Kotwal et al.
patent: 5942405 (1999-08-01), Ames et al.
patent: 6193979 (2001-02-01), Rittershaus et al.
patent: 2003/0096775 (2003-05-01), Graham et al.
patent: 2008/0267980 (2008-10-01), Tomlinson et al.
patent: 9400571 (1994-01-01), None
patent: 9747321 (1997-12-01), None
patent: WO 00/43027 (2000-07-01), None
patent: 0112212 (2001-02-01), None
patent: 03097104 (2003-11-01), None
patent: 2004007553 (2004-01-01), None
patent: 2004043925 (2004-05-01), None
patent: 2006136982 (2006-12-01), None
Niculescu et al. The Role of Complement Activation in Atherosclerosis. Immunologic Research. 2004, vol. 30, No. 1, pp. 73-80.
Amsterdam et al., “Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs,” Am J Physiol., vol. 268, , 1995, pp. H448-H457.
Anderson t al., “Vaccinia Virus Complement Control Protein Ameliorates Hyperacute Xenorejection by Inhibiting Xenoantibody Binding,” Transplantation Proceedings, vol. 34, No. 8, 2002, pp. 3277-3281.
Baker et al., “Studies on the Inhibition of C56-Induced Lysis (Reactive Lysis)—VI. Modulation of C56-Induced Lysis by Polyanions and Polycations,” J. Immunol., vol. 114, 1975, pp. 554-558.
Buerke et al., “Novel Small Molecule Inhibitor of C1s Exerts Cardioprotective Effects in Ischemia-Referfusion Injury in Rabbits,” J Immunol, vol. 167, 2001, pp. 5375-5380.
De Zwaan, et al., “Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction,” Eur Heart J., vol. 21, 2002, pp. 1670-1677.
Englberger et al., “Rosmarinic Acid: A New Inhibitor of Complement C-3-Convertase With Anti-Inflammatory Activity,” Int. J. Immunopharmacol., vol. 10, 1988, pp. 729-737.
Fujii et al., “New Synthetic Inhibitors of C1F, C1 Esterase, Thrombin, Plasmin, Kallikrein and Trypsin,” Biochim. Biophys. Acta, vol. 661, 1981, pp. 342-345.
Granger et al., “Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction: The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) Trial,” Circulation, vol. 108, 2003, pp. 1184-1190.
Hong et al., “Inhibitory Effect of K-76 Monocarboxylic Acid, an Anticomplementary Agent, on the C3b Inactivator System,” J. Immunol., vol. 127, 1981, pp. 104-108.
Horstick et al., “Application of C1-Esterase Inhibitor During Reperfusion of Ischemic Myocardium: Dose-Related Beneficial Versus Detrimental Effects,” Circulation, vol. 104, 2001, pp. 3125-3131.
Inagi et al., “FUT-175 as a potent inhibitor of C5/C3 convertase activity for production of C5a and C3a,” Immunol. Lett., vol. 27, 1991, pp. 49-52.
Kotwal et al., “Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins,” Nature, vol. 335 (6186), 1988, pp. 176-178.
Kotwal et al., “Vaccinia Virus Encodes Two Proteins That Are Structurally Related to Members of the Plasma Serine Protease Inhibitor Superfamily,” J. Virol., vol. 63, 1989, pp. 600-606.
Kotwal et al., “Inhibition of the Complement Cascade by the Major Secretory Protein of Vaccinia Virus,” Science, vol. 250 (4982), 1990, pp. 827-830.
Kroshus et al., “Complement Inhibition With An Anti-C5 Monoclonal Antibody Prevents Acute Cardiac Tissue Injury In An Ex Vivo Model Of Pigs-to-Human Xenotransplantation,” Transplantation, vol. 60, 1995, pp. 1194-1202).
Lazar et al., “Soluble Complement Receptor Type I Limits Damage During Revascularization of Ischemic Myocardium,” Ann Thorac Surg., vol. 65, 1998, pp. 973-977).
Lazar et al., “Total Complement Inhibition: An Effective Stratgey to Limit Ischemic Injury During Coronary Revascularization on Cardiopulmonary Bypass,” Circulation, vol. 100, 1999, pp. 1438-1442.
Mahaffey et al., “Effect of Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Fibrinolysis in Acute Myocardial Infarction: The COMPlement Inhibition in myocardial infarction treated with thromboLYtics (COMPLY) Trial,” Comply; vol. 108, 2003, pp. 1176-1183.
Mckenzie et al., “Regulation of Complement Activity by Vaccinia Virus Complement-Control Protein,” J. Infect. Dis., vol. 166, 1992, pp. 1245-1250.
Morgan et al., “Complement therapeutics; history and current progress,” Mol. Immunol., vol. 40, 2003, pp. 159-170.
Murthy et al., “Crystal Structure of a Complement Control Protein that Regulates Both Pathways of Complement Activiation and Binds Heparan Sulfate Proteoglycans,” Cell, vol. 104, 2001, pp. 301-311.
Park et al., “N-Acetylheparin Pretreatment Reduces Infarct Size in the Rabbit,” Pharmacology; vol. 58, 1999, pp. 120-131.
Reynolds et al., “Vaccinia Virus Complement Control Protein Reduces Inflammation and Improves Spinal Cord Integrity Following Spinal Cord Injury,” Ann. NY Acad. Sci., vol. 1035, 2004, pp. 165-178.
Riley et al., “Recombinant Human Complement C5A Receptor Antagonist Reduces Infarct Size After Surgical Revascularization,” J Thorac Cardiovasc Surg; vol. 120, 2000, pp. 350-358.
Sahu et al., “Inhibition of Human Complement by a C3-Binding Peptide Isolated from a Phage-Displayed Random Peptide Library,” J. Immunol., vol. 157, 1996, pp. 884-891.
Sahu et al., “Interaction of Vaccinia Virus Complement Control Protein with Human Complement Proteins: Factor I-Mediated Degradation of C3b to iC3b1, Inactivates the Alternative Complement Pathway,” J. Immunol., vol. 160, 1998, pp. 5596-5604.
Sahu et al., “Inhibition of Complement by Covalent Attachment of Rosmarinic Acid to Activated C3b,” Biochem. Pharmacol. vol. 57, 1999, pp. 1439-1446.
Smith et al., “Reduction of myocardial reperfusion injury with human soluble complement receptor type 1 (BRL 55730),” Eur J Pharmacol; vol. 236, 1993, pp. 477-481.
Smith et al., “Conserved Surface-Exposed K/R-X-K/R Motifs and Net Positive Charge on Poxvirus Complement Control Proteins Serve as Putative Heparin Binding sites and Contribute to Inhibition of Molecular Interactions with Human Endothelial Cells: a Novel Mechanism for Evasion of Host Defense,” J. Virol., vol. 74, 2000, pp. 5659-5666.
Smith et al., “Mapping of regions within the vaccinia virus complement control protein involved in dose-dependent binding to key complement components and heparin using surface plasmon resonance,” Biochim, Biophys. Acta, vol. 1650, 2003, pp. 30-39.
Tanhehco et al., “Reduction of Myocardial Infarct Size After Ischemia and Reperfusion by the Glycosaminoglycan Pentosan Polysulfate,” J Cardiovasc Pharmacol., vol. 34, 1999, pp. 153-161.
Thorbjornsdottir et al., “Vaccinia Virus Complement Control Protein Diminishes Formation of Atherosclerotic Lesions,” Ann N Y Acad Sci,. vol. 1056, 2005, pp. 1-15.
Vakeva et al., “Myocardial Infarction and Apoptosis After Myocardial Ischemia and Reperfusion: Role of the Terminal Complement Components and Inhibition by Anti-C5 Therapy,” Circulation, vol. 97, 1998, pp. 2259-2267.
Verrier et al., “Terminal Complement Blockade With Pexelizumab During Coronary Artery Bypas
Arason Gudmundur Johann
Kotwal Girish J.
Arason Gudmundur J.
Kotwal Girish J.
Russel Jeffrey E
Stites & Harbison PLLC
Wright Terry L.
LandOfFree
Methods for treatment or prophylaxis of atherosclerosis and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treatment or prophylaxis of atherosclerosis and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treatment or prophylaxis of atherosclerosis and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2630134